Targeting myeloid cells to the brain using non-myeloablative conditioning.

Targeting myeloid cells to the brain using non-myeloablative conditioning.

Bone marrow-derived cells (BMDCs) are able to colonize the central nervous system (CNS) at sites of damage. This ability makes BMDCs an ideal cellular vehicle for transferring therapeutic genes/molecules to the CNS. However, conditioning is required for bone marrow-derived myeloid cells to engraft i...

Full description

Bibliographic Details
Main Authors:	Chotima Böttcher, Francisco Fernández-Klett, Nadine Gladow, Simone Rolfes, Josef Priller
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24244666/?tool=EBI

Similar Items

Reduced Intensity versus Full Myeloablative Conditioning in Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
by: Kamran Alimoghaddam, et al.
Published: (2011-09-01)

A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations
by: Erden Atilla, et al.
Published: (2017-02-01)

Tissue Damage Caused by Myeloablative, but Not Non-Myeloablative, Conditioning before Allogeneic Stem Cell Transplantation Results in Dermal Macrophage Recruitment without Active T-Cell Interaction
by: Peter van Balen, et al.
Published: (2018-02-01)

Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children.
by: Joy Benadiba, et al.
Published: (2018-01-01)

Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome
by: Sagar S. Patel, et al.
Published: (2020-09-01)

Lentiviral delivery of human erythropoietin attenuates hippocampal atrophy and improves cognition in the R6/2 mouse model of Huntington's disease
by: Simone Rolfes, et al.
Published: (2020-10-01)

Prevalence of chimerism after non-myeloablative hematopoietic stem cell transplantation
by: Azulamara da Silva Ruiz, et al.

Tumor vaccination after allogeneic bone marrow cell reconstitution of the non-myeloablatively conditioned tumor-bearing murine host
by: Zöller M
Published: (2004-07-01)

Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity
by: Sarah J. Stephens, MD, et al.
Published: (2016-10-01)

Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy
by: Ronnie Shapira-Frommer, et al.
Published: (2021-05-01)

Reduced-intensity versus myeloablative allogeneic transplantation
by: Daniel J. Weisdorf
Published: (2017-12-01)

Myeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant Cyclophosphamide
by: Scott R. Solomon, et al.
Published: (2016-01-01)

Optimizing Preparative Regimen for Umbilical Cord Blood Transplantation in adult Acute Leukemia Patients: Acute Lymphoblastic Leukemia Requires Myeloablative Conditioning but not Acute Myeloid Leukemia
by: Ja Min Byun, et al.
Published: (2020-07-01)

Non-myeloablative allotransplantation combined with tumour-specific vaccination for the treatment of prostate cancer
by: Michelini, Rodrigo Hess
Published: (2008)

Effects of Myeloablation, Peripheral Chimerism, and Whole-Body Irradiation on the Entry of Bone Marrow-Derived Cells into the Brain
by: Antoine Lampron, et al.
Published: (2012-06-01)

Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.
by: Luis A Sanchez-Perez, et al.
Published: (2013-01-01)

Single-cell mass cytometry reveals complex myeloid cell composition in active lesions of progressive multiple sclerosis
by: Chotima Böttcher, et al.
Published: (2020-08-01)

Non-myeloablative busulfan chimeric mouse models are less pro-inflammatory than head-shielded irradiation for studying immune cell interactions in brain tumours
by: A. Saam Youshani, et al.
Published: (2019-02-01)

TGF-beta signalling contributes to thymic epithelial cell damage and regeneration following myeloablative conditioning and stem-cell transplantation
by: Hauri-Hohl MM, et al.
Published: (2008-09-01)

Splenocytes seed bone marrow of myeloablated mice: implication for atherosclerosis.
by: Lai Wang, et al.
Published: (2015-01-01)

Thrombopoietin from hepatocytes promotes hematopoietic stem cell regeneration after myeloablation
by: Longfei Gao, et al.
Published: (2021-08-01)

Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas
by: Gu Zhenyang, et al.
Published: (2021-03-01)

Infusion of Host-Derived Unlicensed NK Cells Improves Donor Engraftment in Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation
by: Maite Alvarez, et al.
Published: (2021-01-01)

Myeloablative Chemotherapy with Autologous Stem Cell Transplant for Desmoplastic Small Round Cell Tumor
by: Christopher J. Forlenza, et al.
Published: (2015-01-01)

Immune modulatory effect of a novel 4,5-dihydroxy-3,3´,4´-trimethoxybibenzyl from Dendrobium lindleyi.
by: Pichayatri Khoonrit, et al.
Published: (2020-01-01)

Correction: Splenocytes Seed Bone Marrow of Myeloablated Mice: Implication for Atherosclerosis.
by: PLOS ONE Staff
Published: (2015-01-01)

Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation.
by: Elizabeth A de Kort, et al.
Published: (2019-01-01)

Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study
by: Liu Hui, et al.
Published: (2013-02-01)

Preclinical IV busulfan dose-finding study to induce reversible myeloablation in a non-human primate model.
by: Nadim Mahmud, et al.
Published: (2018-01-01)

Long-Term Free Survival of Two Class III β-Thalassemic Patients after Non-Myeloablative Stem Cell Transplantation
by: Mohammad Mahdi Adib Sereshki, et al.
Published: (2020-04-01)

Non-Myeloablative Stem Cell Transplantation in Hematologic Malig¬nancies: An Experience from the Hematology-Oncology and BMT Re¬search Center
by: S Keyhanian, et al.
Published: (2004-03-01)

Non-Myeloablative Stem Cell Transplantation in Hematologic Malig¬nancies: An Experience from the Hematology-Oncology and BMT Re¬search Center
by: Keyhanian S, et al.
Published: (2004-08-01)

Allogeneic transplantation following non-myeloablative conditioning in renal carcinoma. New evidence of the immune mechanisms responsible for the activity of this form of immunotherapy and the pathogenetic role of endogenous retroviruses
by: Camillo Porta
Published: (2011-12-01)

Allogeneic transplantation following non-myeloablative conditioning in renal carcinoma. New evidence of the immune mechanisms responsible for the activity of this form of immunotherapy and the pathogenetic role of endogenous retroviruses
by: Camillo Porta
Published: (2011-12-01)

Experiences of allogeneic hematopoietic cell transplantation following non-myeloablative conditioning regimen in severely comorbid patients with myelofibrosis: case series with a patient presenting with extensive extramedullary hematopoiesis
by: Jae-Ho Yoon, et al.
Published: (2020-06-01)

Low toxicity and favorable clinical and quality of life impact after non-myeloablative autologous hematopoietic stem cell transplant in Crohn’s disease
by: Milton Artur Ruiz, et al.
Published: (2017-10-01)

Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party
by: Marie Thérèse Rubio, et al.
Published: (2017-01-01)

Signal one and two blockade are both critical for non-myeloablative murine HSCT across a major histocompatibility complex barrier.
by: Kia J Langford-Smith, et al.
Published: (2013-01-01)

Successful HLA haploidentical myeloablative stem cell transplantation for aggressive hepatosplenic alpha/beta (αβ) T-cell lymphoma
by: Gioacchino Catania, et al.
Published: (2014-01-01)

Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation
by: Madlen Jentzsch, et al.
Published: (2021-04-01)

Cannot write session to /tmp/vufind_sessions/sess_rej9hoinf3tt4h4kv44hr3m8f0